What is Causing Revvity (RVTY) to Drop 5.1% After Last Earnings Announcement?

Revvity (RVTY) has experienced a downturn of about 5.1% since their last earnings report, performing worse than the S&P 500 during this time frame. Investors may be wondering if this negative trend will continue leading up to the next earnings release or if the company is poised for a turnaround. Taking a closer look at Revvity’s latest earnings report can provide insight into the recent factors affecting the company and how investors and analysts have responded.

During the fourth quarter of 2025, Revvity reported adjusted earnings per share of $1.70, surpassing the Zacks Consensus Estimate of $1.63 by 4.3%. This marks a 19.7% improvement from the previous year’s quarter. Additionally, the company’s GAAP earnings per share from continuing operations was 87 cents, up from 78 cents in the same period last year.

In terms of revenue, Revvity recorded $772.1 million, a 5.9% increase year-over-year. Segmenting their revenue streams, the Life Sciences segment generated $382 million, showing no organic growth compared to the previous year. Meanwhile, the Diagnostics segment saw revenues of $390 million, up 10% year-over-year. Adjusted operating income for the company decreased 3.6% to $229.4 million, with an adjusted operating margin of 29.7%, contracting by 60 basis points.

Looking at the financials, Revvity ended the fourth quarter with cash and cash equivalents of $919.9 million. Cumulatively, their net cash provided by operating activities totaled $582.9 million. When it comes to guidance, Revvity expects adjusted earnings per share for 2026 to fall within the range of $5.35-$5.45, with revenues expected to be between $2.96-$2.99 billion.

In the past month, there has been a negative trend in estimates revision for Revvity, with the consensus estimate shifting -7.66% due to these changes. The company has been assigned a Growth Score of B and a Value Score of C, along with an aggregate VGM Score of B, suggesting a mixed performance across these metrics. Despite the downward trend in estimates, Revvity currently holds a Zacks Rank #3 (Hold), with expectations for an in-line return from the stock in the coming months.

Another player in the medical services industry, HCA Healthcare (HCA), has seen a positive performance with an 8.5% gain over the past month. HCA reported revenues of $19.51 billion in the last quarter, showing a year-over-year increase of 6.7%. Earnings per share for HCA stood at $8.01 for the same period.

In conclusion, Revvity’s recent performance and outlook have been met with mixed responses from investors and analysts. With estimates trending downward and a Zacks Rank of #3 (Hold), the company may face some challenges in the near future. However, positive performances within the medical services industry show some promising signs for the company’s potential growth.